JP2020509050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020509050A5 JP2020509050A5 JP2019547641A JP2019547641A JP2020509050A5 JP 2020509050 A5 JP2020509050 A5 JP 2020509050A5 JP 2019547641 A JP2019547641 A JP 2019547641A JP 2019547641 A JP2019547641 A JP 2019547641A JP 2020509050 A5 JP2020509050 A5 JP 2020509050A5
- Authority
- JP
- Japan
- Prior art keywords
- lineage
- epitope
- cell surface
- hematopoietic
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023192752A JP7854975B2 (ja) | 2017-02-28 | 2023-11-13 | 系統特異的タンパク質の阻害のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464975P | 2017-02-28 | 2017-02-28 | |
| US62/464,975 | 2017-02-28 | ||
| PCT/US2018/020327 WO2018160768A1 (en) | 2017-02-28 | 2018-02-28 | Compositions and methods for inhibition lineage specific proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023192752A Division JP7854975B2 (ja) | 2017-02-28 | 2023-11-13 | 系統特異的タンパク質の阻害のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020509050A JP2020509050A (ja) | 2020-03-26 |
| JP2020509050A5 true JP2020509050A5 (enExample) | 2021-04-15 |
| JP7386082B2 JP7386082B2 (ja) | 2023-11-24 |
Family
ID=63370206
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547641A Active JP7386082B2 (ja) | 2017-02-28 | 2018-02-28 | 系統特異的タンパク質の阻害のための組成物および方法 |
| JP2023192752A Active JP7854975B2 (ja) | 2017-02-28 | 2023-11-13 | 系統特異的タンパク質の阻害のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023192752A Active JP7854975B2 (ja) | 2017-02-28 | 2023-11-13 | 系統特異的タンパク質の阻害のための組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11975029B2 (enExample) |
| EP (1) | EP3589291A4 (enExample) |
| JP (2) | JP7386082B2 (enExample) |
| KR (1) | KR102709603B1 (enExample) |
| CN (1) | CN110662554A (enExample) |
| AU (2) | AU2018229351B2 (enExample) |
| BR (1) | BR112019017751A2 (enExample) |
| CA (1) | CA3054808A1 (enExample) |
| IL (1) | IL268895B2 (enExample) |
| MX (1) | MX2019010196A (enExample) |
| RU (1) | RU2019130504A (enExample) |
| SG (1) | SG11201907870VA (enExample) |
| WO (1) | WO2018160768A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016337525B2 (en) | 2015-10-16 | 2022-01-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| IL268895B2 (en) | 2017-02-28 | 2025-05-01 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| JP2020531535A (ja) * | 2017-08-28 | 2020-11-05 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | Ｃｄ３３標的剤と共に使用するためのｃｄ３３エクソン２欠損型ドナー幹細胞 |
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| WO2020047164A1 (en) * | 2018-08-28 | 2020-03-05 | Vor Biopharma, Inc | Genetically engineered hematopoietic stem cells and uses thereof |
| US11866494B2 (en) * | 2018-08-31 | 2024-01-09 | Innovative Cellular Therapeutics Holdings, Ltd. | CAR T therapy through uses of co-stimulation |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| AU2019336245B2 (en) | 2018-09-07 | 2026-02-26 | Beam Therapeutics Inc. | Compositions and methods for delivering a nucleobase editing system |
| AU2020223314A1 (en) | 2019-02-13 | 2021-08-12 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| SG11202108346WA (en) | 2019-02-13 | 2021-08-30 | Beam Therapeutics Inc | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| WO2020168088A1 (en) * | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating glycogen storage disease type 1a |
| WO2020172638A1 (en) * | 2019-02-22 | 2020-08-27 | The Trustees Of The University Of Pennsylvania | Crispr/cas9 knock-out of cd33 in human hematopoietic stem/ progenitor cells for allogenic transplantation |
| US20220228153A1 (en) | 2019-05-23 | 2022-07-21 | Vor Biopharma Inc. | Compositions and methods for cd33 modification |
| WO2021041971A1 (en) | 2019-08-28 | 2021-03-04 | Vor Biopharma, Inc. | Compositions and methods for cll1 modification |
| US20220333116A1 (en) | 2019-08-28 | 2022-10-20 | Vor Biopharma Inc. | Compositions and methods for cd123 modification |
| WO2021058795A2 (en) * | 2019-09-27 | 2021-04-01 | Stark Labs | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
| CN115279398B (zh) | 2019-09-27 | 2025-07-04 | 比姆医疗股份有限公司 | 治疗液态癌症的组合物和方法 |
| US11723926B2 (en) | 2019-09-27 | 2023-08-15 | Starkage Therapeutics | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
| EP4048790A4 (en) * | 2019-10-22 | 2024-03-27 | Fred Hutchinson Cancer Center | Base editor-mediated cd33 reduction to selectively protect therapeutic cells |
| US20230144405A1 (en) * | 2020-03-31 | 2023-05-11 | Fred Hutchinson Cancer Center | Human anti-cd33 antibodies and uses thereof |
| JP7840865B2 (ja) * | 2020-03-31 | 2026-04-06 | フレッド ハッチンソン キャンサー センター | キメラ抗原受容体ターゲティングｃｄ３３ |
| WO2022047168A1 (en) | 2020-08-28 | 2022-03-03 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| WO2022047165A1 (en) | 2020-08-28 | 2022-03-03 | Vor Biopharma Inc. | Compositions and methods for cd123 modification |
| US20230398219A1 (en) | 2020-09-14 | 2023-12-14 | Vor Biopharma Inc. | Compositions and methods for cd38 modification |
| US20240041932A1 (en) | 2020-09-14 | 2024-02-08 | Vor Biopharma Inc. | Compositions and methods for cd5 modification |
| US20240033290A1 (en) | 2020-09-18 | 2024-02-01 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| US12576151B2 (en) | 2020-09-25 | 2026-03-17 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| WO2022067240A1 (en) | 2020-09-28 | 2022-03-31 | Vor Biopharma, Inc. | Compositions and methods for cd6 modification |
| US20230364146A1 (en) | 2020-09-30 | 2023-11-16 | Vor Biopharma Inc. | Compositions and methods for cd30 gene modification |
| EP4236970A1 (en) * | 2020-10-27 | 2023-09-06 | Vor Biopharma Inc. | Compositions and methods for treating hematopoietic malignancy |
| WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
| CA3201003A1 (en) * | 2020-11-13 | 2022-05-19 | Vor Biopharma Inc. | Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors |
| AU2021413252A1 (en) | 2020-12-31 | 2023-06-08 | Vor Biopharma Inc. | Compositions and methods for cd34 gene modification |
| CN115443333B (zh) * | 2021-04-27 | 2025-04-25 | 上海驯鹿生物技术有限公司 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
| CA3224408A1 (en) | 2021-08-06 | 2023-02-09 | Rosalba LEPORE | Discernible cell surface protein variants for use in cell therapy |
| CA3236152A1 (en) | 2021-11-09 | 2023-05-19 | Vor Biopharma Inc. | Compositions and methods for erm2 modification |
| AU2022409748A1 (en) | 2021-12-16 | 2024-05-23 | Cimeio Therapeutics Ag | Discernible cell surface protein variants of cd117 for use in cell therapy |
| CA3240875A1 (en) | 2021-12-23 | 2023-06-29 | Stefanie Urlinger | Discernible cell surface protein variants of cd45 for use in cell therapy |
| WO2024015925A2 (en) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| CN116850210B (zh) * | 2023-01-17 | 2024-05-31 | 武汉大学 | 用于治疗急性髓系白血病的成分和方法 |
| EP4688850A1 (en) | 2023-04-03 | 2026-02-11 | Universität Basel | Discernible cell surface protein variants of cd33 for use in cell therapy |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030194704A1 (en) | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| WO2009052431A2 (en) | 2007-10-19 | 2009-04-23 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
| PH12012500714A1 (en) | 2009-10-19 | 2012-10-29 | Tristem Trading Cyprus Ltd | Treatment using reprogrammed mature adult cells |
| CA3157027A1 (en) | 2010-07-21 | 2012-01-26 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a t-cell receptor gene |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| LT3401400T (lt) | 2012-05-25 | 2019-06-10 | The Regents Of The University Of California | Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| DK3309248T3 (da) | 2013-05-29 | 2021-08-02 | Cellectis | Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system |
| EP2833591A1 (en) | 2013-07-31 | 2015-02-04 | Siemens Aktiengesellschaft | Subsea data communication interface unit |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| AU2015216875B2 (en) | 2014-02-14 | 2021-02-25 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| US9944709B2 (en) | 2014-03-19 | 2018-04-17 | Cellectis | CD123 specific chimeric antigen receptors for cancer immunotherapy |
| CN106795221B (zh) | 2014-04-03 | 2022-06-07 | 塞勒克提斯公司 | 用于癌症免疫治疗的cd33特异性嵌合抗原受体 |
| WO2015157070A2 (en) | 2014-04-09 | 2015-10-15 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating cystic fibrosis |
| WO2015164740A1 (en) | 2014-04-24 | 2015-10-29 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| WO2015195547A1 (en) | 2014-06-16 | 2015-12-23 | University Of Washington | Methods for controlling stem cell potential and for gene editing in stem cells |
| US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| US9777061B2 (en) | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| JP6736540B2 (ja) | 2014-07-21 | 2020-08-05 | ノバルティス アーゲー | Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置 |
| HUE055583T2 (hu) | 2014-09-16 | 2021-12-28 | Sangamo Therapeutics Inc | Eljárások és készítmények nukleáz által közvetített genommódosításhoz és -javításhoz hematopoetikus õssejtekben |
| KR101799975B1 (ko) | 2014-10-31 | 2017-11-21 | 에스케이씨하이테크앤마케팅(유) | 액정표시장치용 색순도 향상 및 휘도 보상 필름 및 이를 포함하는 액정표시장치 |
| EP3025719B1 (en) * | 2014-11-26 | 2018-09-26 | Miltenyi Biotec GmbH | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| WO2016089433A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| WO2016120218A1 (en) | 2015-01-26 | 2016-08-04 | Cellectis | ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY |
| KR102888521B1 (ko) | 2015-04-06 | 2025-11-19 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna |
| MX2017012939A (es) * | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| EP3173092B1 (en) | 2015-04-22 | 2019-06-26 | CureVac AG | Rna containing composition for treatment of tumor diseases |
| GB201507119D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| JP6985934B2 (ja) * | 2015-04-29 | 2021-12-22 | フレッド ハッチンソン キャンサー リサーチ センター | 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用 |
| EP3294896A1 (en) | 2015-05-11 | 2018-03-21 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| CN107847568B (zh) | 2015-06-16 | 2022-12-20 | 豪夫迈·罗氏有限公司 | 抗cll-1抗体和使用方法 |
| AU2016337525B2 (en) | 2015-10-16 | 2022-01-20 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| SG10202104041PA (en) | 2015-10-23 | 2021-06-29 | Harvard College | Nucleobase editors and uses thereof |
| EP3370741B1 (en) | 2015-11-04 | 2025-10-08 | The Trustees of the University of Pennsylvania | Methods and compositions for gene editing in hematopoietic stem cells |
| CA3004743A1 (en) | 2015-11-24 | 2017-06-01 | Cellerant Therapeutics, Inc. | Humanized anti-cll-1 antibodies |
| WO2017172981A2 (en) * | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| US11499168B2 (en) | 2016-04-25 | 2022-11-15 | Universitat Basel | Allele editing and applications thereof |
| EP3468994A1 (en) | 2016-06-08 | 2019-04-17 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| JP7114490B2 (ja) | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP7195154B2 (ja) | 2016-07-06 | 2022-12-23 | セレクティス | 初代免疫細胞における逐次遺伝子編集 |
| PL3529262T3 (pl) | 2016-10-21 | 2021-12-27 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Sposoby wspomagania odpowiedzi limfocytów t |
| HUE067685T2 (hu) | 2016-11-02 | 2024-11-28 | Univ Basel | Immunológiailag megkülönböztethetõ sejtfelszíni variánsok sejtterápiában történõ alkalmazásra |
| MX420023B (es) | 2016-12-30 | 2025-01-14 | Editas Medicine Inc | Moléculas guía sintéticas, composiciones y métodos relacionados con éstas. |
| IL268895B2 (en) | 2017-02-28 | 2025-05-01 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| WO2018165629A1 (en) | 2017-03-10 | 2018-09-13 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| WO2018176009A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| KR20190140943A (ko) | 2017-04-24 | 2019-12-20 | 메모리얼 슬로안 케터링 캔서 센터 | 항-cd33 항체 제제 |
| JP2020531535A (ja) | 2017-08-28 | 2020-11-05 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | Ｃｄ３３標的剤と共に使用するためのｃｄ３３エクソン２欠損型ドナー幹細胞 |
| US10704938B2 (en) | 2018-01-31 | 2020-07-07 | Hydroacoustics, Inc. | Pumpjack production well including fluid sensor having 2-dimensional venturi and capacitive flow sensor |
| WO2019157326A1 (en) | 2018-02-08 | 2019-08-15 | Zymergen Inc. | Genome editing using crispr in corynebacterium |
| TWI669677B (zh) | 2018-03-07 | 2019-08-21 | 光陽工業股份有限公司 | 充電座管理方法、用於充電座管理方法的伺服器及充電座 |
| WO2020047164A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma, Inc | Genetically engineered hematopoietic stem cells and uses thereof |
| US20220226375A1 (en) | 2018-11-07 | 2022-07-21 | Crispr Therapeutics Ag | Anti-cd33 immune cell cancer therapy |
| JP2022518463A (ja) | 2019-01-16 | 2022-03-15 | ビーム セラピューティクス インク． | 抗新生物活性および免疫抑制抵抗性の増強を有する改変された免疫細胞 |
| AU2020209218A1 (en) | 2019-01-16 | 2021-07-29 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
| SG11202108346WA (en) | 2019-02-13 | 2021-08-30 | Beam Therapeutics Inc | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| US20220228153A1 (en) | 2019-05-23 | 2022-07-21 | Vor Biopharma Inc. | Compositions and methods for cd33 modification |
| EA202191979A1 (ru) | 2019-05-24 | 2021-11-01 | Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк | Композиции и способы ингибирования линиеспецифических антигенов |
| WO2021041971A1 (en) | 2019-08-28 | 2021-03-04 | Vor Biopharma, Inc. | Compositions and methods for cll1 modification |
| US20220333116A1 (en) | 2019-08-28 | 2022-10-20 | Vor Biopharma Inc. | Compositions and methods for cd123 modification |
-
2018
- 2018-02-28 IL IL268895A patent/IL268895B2/en unknown
- 2018-02-28 JP JP2019547641A patent/JP7386082B2/ja active Active
- 2018-02-28 SG SG11201907870VA patent/SG11201907870VA/en unknown
- 2018-02-28 CN CN201880026602.0A patent/CN110662554A/zh active Pending
- 2018-02-28 KR KR1020197028404A patent/KR102709603B1/ko active Active
- 2018-02-28 MX MX2019010196A patent/MX2019010196A/es unknown
- 2018-02-28 WO PCT/US2018/020327 patent/WO2018160768A1/en not_active Ceased
- 2018-02-28 BR BR112019017751-5A patent/BR112019017751A2/pt not_active Application Discontinuation
- 2018-02-28 US US16/489,407 patent/US11975029B2/en active Active
- 2018-02-28 RU RU2019130504A patent/RU2019130504A/ru unknown
- 2018-02-28 EP EP18760400.4A patent/EP3589291A4/en active Pending
- 2018-02-28 CA CA3054808A patent/CA3054808A1/en active Pending
- 2018-02-28 AU AU2018229351A patent/AU2018229351B2/en active Active
-
2023
- 2023-11-13 JP JP2023192752A patent/JP7854975B2/ja active Active
-
2024
- 2024-03-28 US US18/620,496 patent/US20240350550A1/en active Pending
- 2024-04-03 AU AU2024202117A patent/AU2024202117A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250034217A1 (en) | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof | |
| Ben-Shmuel et al. | Unleashing natural killer cells in the tumor microenvironment–the next generation of immunotherapy? | |
| RU2019130504A (ru) | Композиции и способы ингибирования линиеспецифических белков | |
| KR102483822B1 (ko) | 태그된 키메라 이펙터 분자 및 그의 리셉터 | |
| TWI775768B (zh) | 新穎t細胞受器及使用其之免疫治療 | |
| RU2756247C2 (ru) | Генетически модифицированные гамма дельта т-клетки | |
| KR102095700B1 (ko) | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 | |
| Wang et al. | T-cell-based immunotherapy for osteosarcoma: challenges and opportunities | |
| JP2019536480A (ja) | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 | |
| EP3025719B1 (en) | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases | |
| US20220251572A1 (en) | Immune cells defective for suv39h1 | |
| US20190085081A1 (en) | Chimeric antigen receptor | |
| CN110494160A (zh) | T细胞受体及其针对prame阳性癌症的免疫治疗 | |
| KR20190036551A (ko) | Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료 | |
| JP2016520074A5 (enExample) | ||
| US20250152717A1 (en) | Binding proteins and engineered cells specific for neoantigens and uses thereof | |
| US20230348854A1 (en) | Chimeric antigen receptors (cars) targeting natural killer cells | |
| CA3132458A1 (en) | Cd147 chimeric antigen receptors and methods of use | |
| JP2022514320A (ja) | Ｃｄ２２特異的なｔ細胞受容体およびｂ細胞悪性腫瘍の処置のための養子ｔ細胞療法 | |
| KR20200085776A (ko) | 신규한 감마 델타 t-세포 수용체 및 이의 리간드 | |
| WO2019140278A1 (en) | Immunotherapy targeting core binding factor antigens | |
| CA3250186A1 (en) | Specific binding proteins for RAS neo-antigens and their uses | |
| JP2024502170A5 (enExample) | ||
| CN119912567B (zh) | 一种表达靶向B7-H3的嵌合抗原受体的Vγ9Vδ2 T细胞及其应用 | |
| JP7859985B2 (ja) | Ｃｄ３３を標的にするキメラ抗原受容体 |